Roche reported a 5% year-on-year decline in first-quarter sales, totaling 14.7 billion Swiss francs ($18.7 billion), attributing the drop primarily to the strength of the Swiss franc and increased generic competition for some of its older drugs [1]. However, when measured on a constant currency basis, sales actually rose by 6%, highlighting the significant impact of currency fluctuations on the company's reported results [1]. The Swiss franc appreciated against most currencies, notably the U.S. dollar, which Roche said had a substantial effect on its Swiss franc-reported figures. Specifically, the Swiss franc fell 12% against the U.S. dollar in 2025 and is down another 1% so far this year [1].
CEO Thomas Schinecker defended the company's performance, emphasizing that sales reported in U.S. dollars increased by 9% and noting that Roche spends most of its money and holds most of its debt in the U.S. [1]. Schinecker also pointed out that Roche recently acquired another company in the U.S. and plans to continue investing there, stating, "We will continue to invest in the U.S., and we don't see that as a major issue" [1].
The pharmaceutical sector in Europe is facing pressure due to an impending loss of exclusivity for older medicines by the end of the decade, which is expected to increase generic competition [1]. In response, Roche is focusing on entering the weight-loss drug market, aiming to become a top-three player with its experimental drug CT-388, competing with current market leaders Novo Nordisk and Eli Lilly [1]. Schinecker stated that Roche is targeting a double-digit market share in the weight-loss segment [1].
No specific analyst opinions or immediate market reactions were provided in the article.
CONCLUSION
Roche's Q1 results were negatively impacted by currency headwinds and generic competition, but the company is emphasizing its U.S. investments and future growth in the weight-loss drug market. CEO Schinecker remains optimistic about Roche's strategic direction, particularly its ambitions for CT-388. The market impact is medium, with currency volatility and sector pressures balanced by forward-looking growth initiatives.